Medicare's Coverage and Analysis Group expects to spend an entire year reviewing Dendreon Corp.'s (Nasdaq: DNDN) prostate cancer treatment Provenge. The stock price plunged $3.41 to $28.92.
Medicare Reviewing Dendreon's Provenge
July 01, 2010 at 12:14 PM EDT